Skip to main navigation Skip to search Skip to main content

Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1

  • Thomas Kryza
  • , Tashbib Khan
  • , Scott Lovell
  • , Brittney S Harrington
  • , Julia Yin
  • , Sean Porazinski
  • , Marina Pajic
  • , Hannu Koistinen
  • , Juha K Rantala
  • , Tobias Dreyer
  • , Viktor Magdolen
  • , Ute Reuning
  • , Yaowu He
  • , Edward W Tate
  • , John D Hooper
  • Mater Research Institute-The University of Queensland
  • Engineering and Physical Sciences Research Council
  • Imperial College London
  • White City Campus
  • Stanford University Medical Center
  • The Garvan Institute of Medical Research
  • CQUniversity Sydney
  • Cancer Council New South Wales
  • St Vincent's Clinical School
  • Oita University
  • University of Sydney
  • University of Helsinki and Helsinki University Hospital
  • Misvik Biology
  • Technical University of Munich

Research output: Contribution to journalArticlepeer-review

21   Link opens in a new tab Citations (SciVal)

Abstract

CUB domain-containing protein 1 (CDCP1) is an oncogenic orphan transmembrane receptor and a promising target for the detection and treatment of cancer. Extracellular proteolysis of CDCP1 by poorly defined mechanisms induces pro-metastatic signaling. We describe a new approach for the rapid identification of proteases responsible for key proteolytic events using a substrate-biased activity-based probe (sbABP) that incorporates a substrate cleavage motif grafted onto a peptidyl diphenyl phosphonate warhead for specific target protease capture, isolation and identification. Using a CDCP1-biased probe, we identify urokinase (uPA) as the master regulator of CDCP1 proteolysis, which acts both by directly cleaving CDCP1 and by activating CDCP1-cleaving plasmin. We show that coexpression of uPA and CDCP1 is strongly predictive of poor disease outcome across multiple cancers and demonstrate that uPA-mediated CDCP1 proteolysis promotes metastasis in disease-relevant preclinical in vivo models. These results highlight CDCP1 cleavage as a potential target to disrupt cancer and establish sbABP technology as a new approach to identify disease-relevant proteases.

Original languageEnglish
Pages (from-to)776-783
Number of pages8
JournalNature Chemical Biology
Volume17
Issue number7
Early online date15 Apr 2021
DOIs
Publication statusPublished - 31 Jul 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Animals
  • Antigens, Neoplasm/chemistry
  • Cell Adhesion Molecules/chemistry
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Molecular Structure
  • Peptide Hydrolases/analysis
  • Substrate Specificity

Fingerprint

Dive into the research topics of 'Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1'. Together they form a unique fingerprint.

Cite this